American Society of Hematology

American Society of Hematology
The American Society of Hematology’s 59th Annual Meeting and Exposition will be held December 9-12, 2017, in Atlanta, Georgia. Professionals from around the world will present and discuss their research and latest developments in malignant and non-malignant hematology. Sign up for our daily e-mail blasts , and check back here during the conference for our complete meeting coverage.
May 26, 2018
Guidelines can help address issues of cost and variation, especially in complex diseases, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.
May 09, 2018
The purpose of evidence-based guidelines is to reduce the level of variation, improve outcomes, and reduce costs, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.
May 01, 2018
Chimeric antigen receptor (CAR) T-cell treatments are still new enough that there are still unknown regarding long-term side effects, which is something patients need to understand before they undergo treatment, said Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
April 26, 2018
Physician involvement, patient input, and accuracy are the most important aspects of successfully implementing guidelines, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.
April 18, 2018
Thomas LeBlanc, MD, of the Duke Cancer Institute, addresses the importance of adding a palliative care specialist to the cancer care team.
 
April 17, 2018
Since patients who receive CAR T-cell therapy experience unique adverse events, there will need to be education for providers who care for these patients, explained Stephen Schuster, MD, of the Perelman School of Medicine.
April 09, 2018
While clinicians can have a bad reaction to the idea of “cookbook medicine,” it can really result in patients getting the best treatment, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.
 
April 07, 2018
While there has been progress with using chimeric antigen receptor (CAR) T cells to treat multiple myeloma, these treatments aren’t ready for prime time, said Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.
April 02, 2018
Thomas LeBlanc, MD, of the Duke Cancer Institute, discusses how palliative care has evolved over the past decade for patients with blood cancers.
March 21, 2018
Thomas LeBlanc, MD, Duke Cancer Institute, addresses the ways palliative care and hospice can improve end-of-life outcomes for patients with blood cancers.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!